IRVING, Texas, Feb. 2 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced that Kirk Meares, R.Ph., has rejoined the Company as Vice President, Sales and Marketing, Veterinary and Oral Care Products.
Mr. Meares was instrumental in the introduction of Carrington Dermal Wound Gel, which was the first Carrington product on the market. He continued to sell Carrington wound care, radiation care and oral care products for a number of years, with responsibilities ranging from an independent sales representative to Vice President, Sales and Marketing. During this tenure, Mr. Meares gained an in-depth knowledge of wound management, including dermal wounds, radiation induced wounds and oral wounds. He will use that knowledge and experience to grow the veterinary wound management and oral care product lines.
Carlton E. Turner, president and CEO, stated, "Kirk has a thorough understanding of the dynamics of getting a product through the distribution system to the end user. We at Carrington look forward to his leadership in growing our veterinary and oral care line of products."
"After being away 5 years, I look forward to re-joining the Carrington management team," stated Mr. Meares. "I intend to grow the veterinary product line by re-vitalizing the present CarraVet(R) products with improvements in product, labeling, literature and product visibility. We will also introduce a separate product line directed toward equine wound management as well as a retail product line for pets. Prescription medical device dental products (SaliCept(TM)) for dry socket, brace irritation, mouth ulcers, mucositis and stomatitis will be made available to dentists through their preferred wholesale dental supplier, increasing product visibility and sales. A retail consumer product line will be made available through various retail outlets so consumers can easily obtain products for canker sores, etc."
Mr. Meares may be reached at (972) 518-1300, ext. 661 or via E-mail: kmeares@carringtonlabs.com .
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com .
Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed November 14, 2005.
Carrington Laboratories, Inc.CONTACT: Carlton E. Turner, Chief Executive Officer of CarringtonLaboratories, Inc., +1-972-518-1300
Web site: http://www.carringtonlabs.com/
